Please log in to determine if you are eligible to purchase PT Programs.
NGS HEMATOLOGIC MALIGNANCIES - NGSHM
Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).
Challenges per Shipment
Number of Shipments
Two shipments per year
This is a methods‑based proficiency challenge for laboratories performing targeted next‑generation sequencing of genes or mutation hotspots in hematologic malignancies. Laboratories will be asked to identify somatic single nucleotide variants and small insertions or deletions in some of these genes: ASXL1, ATM, BRAF, CALR, CEBPA, CREBBP, CSF3R, DNMT3A, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KMT2D, MPL, MYD88, NOTCH1, NPM1, SF3B1, SRSF2, TET2, TP53, U2AF1.
This Survey includes variants present with a variant allele fraction (VAF) potentially as low as 5%.